{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:22:04Z","timestamp":1795159324757,"version":"4.10.3"},"reference-count":112,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,3,3]],"date-time":"2024-03-03T00:00:00Z","timestamp":1709424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Cystic fibrosis (CF) is a multifaceted disorder predominantly investigated for its pulmonary manifestations, yet patients with CF also exhibit a spectrum of extrapulmonary manifestations, notably those involving the hepatobiliary system. The latter constitutes the third leading cause of morbidity and mortality in individuals with CF. Cystic fibrosis-related liver disease (CFLD), with an escalating prevalence, manifests diverse clinical presentations ranging from hepatomegaly to cirrhosis and hepatopulmonary syndrome. Consequently, early detection and appropriate management are imperative for sustaining the health and influencing the quality of life of CF patients afflicted with CFLD. This review aims to consolidate existing knowledge by providing a comprehensive overview of hepatobiliary manifestations associated with CF. It delineates the clinical hepatobiliary manifestations, diagnostic methodologies, incorporating minimally invasive markers, and therapeutic approaches, encompassing the impact of novel CFTR modulators on CFLD. Given the exigency of early diagnosis and the intricate management of CFLD, a multidisciplinary team approach is essential to optimize care and enhance the quality of life for this subset of patients. In conclusion, recognizing CF as more than solely a pulmonary ailment, the authors underscore the imperative for further clinical investigations to establish a more robust evidence base for CFLD management within the continuum of this chronic disease.<\/jats:p>","DOI":"10.3390\/diagnostics14050538","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T08:03:47Z","timestamp":1709539427000},"page":"538","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diagnosis, Management, and Prognosis of Cystic Fibrosis-Related Liver Disease in Children"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-378X","authenticated-orcid":false,"given":"Dana-Teodora","family":"Anton-P\u0103duraru","sequence":"first","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"},{"name":"\u201cSf. Maria\u201d Children Emergency Hospital, 700309 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Nicoleta","family":"Azoic\u0103i","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"},{"name":"\u201cSf. Maria\u201d Children Emergency Hospital, 700309 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8551-3053","authenticated-orcid":false,"given":"Felicia","family":"Trofin","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Interdisciplinarity-Microbiology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Mariela","family":"Murgu","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"},{"name":"\u201cSf. Maria\u201d Children Emergency Hospital, 700309 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana Elena","family":"M\u00eendru","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"},{"name":"\u201cSf. Maria\u201d Children Emergency Hospital, 700309 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Simona","family":"Bocec","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-6476","authenticated-orcid":false,"given":"Codru\u021ba Olimpiada Iliescu","family":"Hali\u021bchi","sequence":"additional","affiliation":[{"name":"Department of Mother and Child Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u1e63i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Rusu","family":"Zota","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Clinical Pharmacology and Algesiology, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"P\u0103duraru","sequence":"additional","affiliation":[{"name":"\u201cDr. C. I. Parhon\u201d Clinical Hospital, 700503 Ia\u1e63i, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6970-0097","authenticated-orcid":false,"given":"Eduard Vasile","family":"Nastase","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II\u2014Infectious Diseases, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Clinical Hospital of Infectious Diseases \u201cSf. Parascheva\u201d, 700116 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,3]]},"reference":[{"key":"ref_1","unstructured":"Ingrith, M. (2016). Pediatrie, Editura \u201cGr.T. Popa\u201d, UMF."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota","volume":"8","author":"Fiorotto","year":"2019","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_3","unstructured":"CFDB\u2014Cystic Fibrosis DataBase (2023, December 15). Liver Diseases. Available online: https:\/\/www.cfdb.eu\/en\/topics\/detail\/code\/173."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3476(05)83478-X","article-title":"The changing epidemiology of cystic fibrosis","volume":"122","author":"FitzSimmons","year":"1993","journal-title":"J. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.23736\/S0026-4946.20.05895-8","article-title":"Cystic fibrosis-associated liver disease in children","volume":"72","author":"Wasuwanich","year":"2020","journal-title":"Minerva Pediatr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/00365521.2018.1534986","article-title":"Evaluation of noninvasive markers for the diagnosis of Cystic Fibrosis liver disease","volume":"53","author":"Alexopoulou","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_7","first-page":"404","article-title":"New Algorithm for the Integration of Ultrasound Into Cystic Fibrosis Liver Disease Screening","volume":"69","author":"Sellers","year":"2019","journal-title":"JPGN"},{"key":"ref_8","unstructured":"Stana, B., Bozomitu, L., Grigora\u1e63, S., and Popovici, P. (2023, December 17). Liver Involvement in Cystic Fibrosis in Children. Available online: https:\/\/www.medichub.ro\/reviste-de-specialitate\/pediatru-ro\/liver-involvement-in-cystic-fibrosis-in-children-id-8304-cmsid-64."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2020.07.018","article-title":"Barrier to using APRI and GPR as identifiers of cystic fibrosis liver disease","volume":"20","author":"Sellers","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_11","unstructured":"Leung, H.D., Narkewicz, R.M., and Cystic Fibrosis: Hepatobiliary Disease (2023, December 17). UpToDate. Available online: https:\/\/medilib.ir\/uptodate\/show\/99126."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MPG.0b013e31829206a0","article-title":"Application and limitations of transient liver elastography in children","volume":"57","author":"Goldschmidt","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"French CF Modifier Gene Study Investigators. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients","volume":"69","author":"Debray","year":"2019","journal-title":"Hepatology"},{"key":"ref_15","unstructured":"Betapudi, B., Aleem, A., and Kothadia, J.P. (2023, December 16). Cystic Fibrosis and Liver Disease, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556086."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/01.mpg.0000226390.02355.52","article-title":"Liver Disease in Cystic Fibrosis","volume":"43","author":"Colombo","year":"2006","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/jhep.2003.50403","article-title":"Risk factors for the development of cystic fibrosis related liver disease","volume":"38","author":"Slieker","year":"2003","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Staufer, K. (2020). Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228586"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Thavamani, A., Salem, I., Sferra, T., and Sankararaman, S. (2011). Impact of Altered Gut Microbiota and Its Metabolites in Cystic Fibrosis. Metabolites, 11.","DOI":"10.3390\/metabo11020123"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4254\/wjh.v13.i11.1727","article-title":"Cystic fibrosis associated liver disease in children","volume":"13","author":"Valamparampil","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.2009.1295","article-title":"Genetic modifiers of liver disease in cystic fibrosis","volume":"302","author":"Bartlett","year":"2009","journal-title":"JAMA"},{"key":"ref_22","first-page":"22","article-title":"Cystic Fibrosis liver disease: A condition in need of structured transition and continuity of care","volume":"9","author":"Hercun","year":"2019","journal-title":"Can. Liver J."},{"key":"ref_23","first-page":"146","article-title":"Cystic Fibrosis-associated Liver Disease: A Review Article","volume":"5","author":"Kianifar","year":"2018","journal-title":"Rev. Clin. Med."},{"key":"ref_24","first-page":"136","article-title":"Liver Disease in Cystic Fibrosis","volume":"9","author":"Klincewicz","year":"2014","journal-title":"Prz. Gastroenterol."},{"key":"ref_25","unstructured":"Wiecek, S. (2019). Cystic Fibrosis\u2014Heterogeneity and Personalized Treatment, IntechOpen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.paed.2017.07.010","article-title":"Liver disease in cystic fibrosis","volume":"27","year":"2017","journal-title":"Pediatr. Child Health"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"153301549","DOI":"10.1002\/hep4.1266","article-title":"Diet-Induced Dysbiosis and Genetic Background Synergize with Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice","volume":"2","author":"Debray","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_28","first-page":"543","article-title":"Ursodeoxycholic acid effects on Cystic Fibrosis liver disease","volume":"63","author":"Pop","year":"2015","journal-title":"Farmacia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: Pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Anand, S., and Mande, S.S. (2022). Host-microbiome interactions: Gut-Liver axis and its connection with other organs. NPJ Biofilms Microbiomes, 8.","DOI":"10.1038\/s41522-022-00352-6"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"34055","DOI":"10.1038\/srep34055","article-title":"Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Shao, L., Ling, Z., Chen, D., Liu, Y., Yang, F., and Li, L. (2018). Disorganized gut microbiome contributed to liver cirrhosis progression: A meta-omics-based study. Front. Microbiol., 9.","DOI":"10.3389\/fmicb.2018.03166"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.aohep.2019.06.020","article-title":"Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis","volume":"18","author":"Liu","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rager, S.L., and Zeng, M.Y. (2023). The Gut\u2013Liver Axis in Pediatric Liver Health and Disease. Microorganisms, 11.","DOI":"10.3390\/microorganisms11030597"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000371670","article-title":"Bile Acids as Hormones: The FXR-FGF15\/19 Pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"Dig. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.28000","article-title":"Stimulation of nuclear receptor peroxisome proliferator-activated receptor-\u03b3 limits NF-\u03baB-dependent inflammation in mouse cystic fibrosis biliary epithelium","volume":"62","author":"Scirpo","year":"2015","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000001728","article-title":"Variceal Hemmmmorhage and Adverse Liver Outcomes in Patients with Cystic Fibrosis Cirrhosis","volume":"66","author":"Ye","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_38","unstructured":"Kliegman, R., St Gene, J., Blum, N., Shah, S., Tasker, R., and Karen, W. (2020). Nelson Textbook of Pediatrics, Elsevier. [21st ed.]."},{"key":"ref_39","first-page":"680","article-title":"Cystic Fibrosis below the Diaphragm: Abdominal Findings in Adult Patients","volume":"35","author":"Lavelle","year":"2015","journal-title":"Radio Graph."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/jgh.12785","article-title":"Cystic fibrosis: An update for clinicians. Part 2: Hepatobiliary and pancreatic manifestations","volume":"29","author":"Ledder","year":"2014","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jcf.2017.07.002","article-title":"Cystic Fibrosis-related cirrhosis","volume":"16","author":"Leung","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1148\/rg.263055101","article-title":"Review of the abdominal manifestations of cystic Fibrosis in the adult patient","volume":"26","author":"Robertson","year":"2006","journal-title":"Radiographics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3389\/fphar.2019.01515","article-title":"Paracrine fibroblast growth factor 1 functions as potent therapeutic agent for intrahepatic cholestasis by downregulating synthesis of bile acid","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_44","first-page":"100283","article-title":"Cystic fibrosis related liver disease and endocrine considerations","volume":"27","author":"Sherwood","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fendo.2018.00020","article-title":"Cystic Fibrosis-Related Diabetes","volume":"9","author":"Kayani","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s11605-009-0924-5","article-title":"Distal intestinal obstruction syndrome (DIOS) in patients with cystic fibrosis after lung transplantation","volume":"13","author":"Morton","year":"2009","journal-title":"J. Gastrointest. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1378\/chest.123.1.37","article-title":"GI complications after lung transplantation in patients with cystic fibrosis","volume":"123","author":"Gilljam","year":"2003","journal-title":"Chest"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1600-6143.2011.03904.x","article-title":"Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis","volume":"12","author":"Dowman","year":"2012","journal-title":"Am. J. Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cgh.2012.11.006","article-title":"Gastrointestinal Complications of Cystic Fibrosis","volume":"11","author":"Gelfond","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MPG.0000000000000758","article-title":"Increase of Serum \u03b3-Glutamyltransferase Associated with Development of Cirrhotic Cystic Fibrosis Liver Disease","volume":"61","author":"Bodewes","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2016.08.002","article-title":"Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen","volume":"16","author":"Woodruff","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00330-018-5650-5","article-title":"The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study","volume":"29","author":"Staufer","year":"2019","journal-title":"Eur. Radiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpeds.2019.12.033","article-title":"Heterogeneous Liver on Research Ultrasound Identifies Children with Cystic Fibrosis at High Risk of Advanced Liver Disease: Interim Results of a Prospective Observational Case-Controlled Study","volume":"219","author":"Siegel","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s00261-021-03396-y","article-title":"Liver fibrosis quantification","volume":"47","author":"Venkatesh","year":"2022","journal-title":"Abdom. Radiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MPG.0b013e31812e56ff","article-title":"Liver stiffness measurement in children using FibroScan: Feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy","volume":"45","author":"Rebouissoux","year":"2007","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MPG.0000000000001822","article-title":"Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography","volume":"66","author":"Gominon","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba","year":"2020","journal-title":"Gut"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.cgh.2019.03.015","article-title":"Accuracy of Transient Elastography Data Combined with APRI in Detection and Staging of Liver Disease in Pediatric Patients with Cystic Fibrosis","volume":"17","author":"Lewindon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.dld.2012.04.008","article-title":"TIMP-1\/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease","volume":"44","author":"Rath","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Karlas, T., Neuschulz, M., Oltmanns, A., G\u00fcttler, A., Petroff, D., Wirtz, H., Mainz, J.G., M\u00f6ssner, J., Berg, T., and Tr\u00f6ltzsch, M. (2012). Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042139"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ultrasmedbio.2015.11.011","article-title":"Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis","volume":"42","author":"Verdievel","year":"2016","journal-title":"Ultrasound Med. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/liv.12113","article-title":"Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease","volume":"33","author":"Kitson","year":"2013","journal-title":"Liver Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1155\/2015\/138530","article-title":"Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis","volume":"29","author":"Sadler","year":"2015","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcf.2012.12.013","article-title":"Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis","volume":"12","author":"Schlueter","year":"2013","journal-title":"J. Cyst. Fibros."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4798136","DOI":"10.1155\/2022\/4798136","article-title":"Assessment of Liver Fibrosis with the Use of Elastography in Paediatric Patients with Diagnosed Cystic Fibrosis","volume":"2022","author":"Wiecek","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/MPG.0000000000002872","article-title":"Extended Screening for Cystic Fibrosis-related Liver Disease Including Elastography in Children and Adolescents","volume":"71","author":"Jensen","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MCP.0000000000000428","article-title":"Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease","volume":"23","author":"Bertolini","year":"2017","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: A prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_70","first-page":"CD012056","article-title":"Interventions for preventing and managing advanced liver disease in cystic fibrosis","volume":"3","author":"Palaniappan","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_71","first-page":"CD008760","article-title":"Capsule endoscopy for the diagnosis of oesophageal varices in people with chronic liver disease or portal vein thrombosis","volume":"2014","author":"Colli","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3748\/wjg.v26.i21.2839","article-title":"Non-invasive prediction model for high-risk esophageal varices in the Chinese population","volume":"26","author":"Yang","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0016-5085(95)90407-7","article-title":"Ursodeoxycholate increases cytosolic 472 calcium concentration and activates Cl-currents in a biliary cell line","volume":"109","author":"Shimokura","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/cld.583","article-title":"Cystic Fibrosis-related Liver Diseases: New Paradigm for Treatment Based on Pathophysiology","volume":"8","author":"Fiorotto","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/hep.1840160412","article-title":"Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose-response study","volume":"16","author":"Colombo","year":"1992","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/pr.2011.759","article-title":"Ursodeoxycholic Acid for Cystic Fibrosis Related Liver Disease, Our Experience","volume":"70","author":"Mujtaba","year":"2011","journal-title":"Pediatr. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpeds.2016.05.008","article-title":"Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease","volume":"177","author":"Colombo","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jcf.2016.07.009","article-title":"Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients","volume":"15","author":"Houwen","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_79","first-page":"CD000222","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","volume":"9","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jcf.2021.03.014","article-title":"Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study","volume":"21","author":"Colombo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.23631","article-title":"Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression","volume":"52","author":"Sinakos","year":"2010","journal-title":"Hepatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2\u20135 years with cystic fibrosis and a CFTR gating mutation (KIWI): An open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcf.2018.09.001","article-title":"IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation","volume":"18","author":"Doktorova","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_89","first-page":"259","article-title":"Liver function tests in F508del homozygous paediatric patients with cystic fibrosis taking lumacaftor\/ivacaftor combination therapy","volume":"114","author":"Paluck","year":"2021","journal-title":"Ir. Med. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"Drummond","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e0010","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_92","first-page":"A219","article-title":"Evaluation of the impact of cystic fibrosis modifier therapies on liver function in children and young adults","volume":"108","author":"Kennedy","year":"2023","journal-title":"Arch. Dis. Child."},{"key":"ref_93","unstructured":"Romanian Ministery of Health (2023, December 29). Raport de Evaluare a Tehnologiilor Medicale DCI: Ivacaftorum + Ivacaftorum\/Tezacaftorum\/Elexacaftrorum, Available online: https:\/\/www.anm.ro\/_\/EVALUARE%20TEHNOLOGII%20MEDICALE\/MUTARI\/10005_2022_Kalydeco+Kaftrio.pdf."},{"key":"ref_94","first-page":"440","article-title":"Systematic Review of Probiotics for Cystic Fibrosis Patients: Moving Forward","volume":"72","author":"Taminato","year":"2020","journal-title":"Minerva Pediatr."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/s41598-020-58069-5","article-title":"Beneficial bile acid metabolism from Lactobacillus plantarum of food origin","volume":"10","author":"Prete","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Esposito, S., Testa, I., Mariotti Zani, E., Cunico, D., Torelli, L., Grandinetti, R., Fainardi, V., Pisi, G., and Principi, N. (2022). Probiotics Administration in Cystic Fibrosis: What Is the Evidence?. Nutrients, 14.","DOI":"10.3390\/nu14153160"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/lt.25421","article-title":"A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease","volume":"25","author":"Freeman","year":"2019","journal-title":"Liver Transpl."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature10998","article-title":"A PPARc\u2013FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis","volume":"485","author":"Jonker","year":"2012","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","article-title":"A vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response","volume":"153","author":"Ding","year":"2013","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1053\/j.gastro.2011.06.052","article-title":"Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-\u03baB-mediated inflammatory response in mice","volume":"141","author":"Fiorotto","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/hep.29400","article-title":"Src kinase inhibition reduces inflammatory and cytoskeletal changes in \u0394F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy","volume":"67","author":"Fiorotto","year":"2018","journal-title":"Hepatology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ppul.20286","article-title":"Diagnosis and treatment of intestinal malabsorption in cystic fibrosis","volume":"41","author":"Littlewood","year":"2006","journal-title":"Pediatr. Pulmonol."},{"key":"ref_103","first-page":"CD012798","article-title":"Interventions for treating distal intestinal obstruction syndrome (DIOS) in Cystic Fibrosis","volume":"8","author":"Green","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/MPG.0000000000003605","article-title":"Health-related Quality of Life in a Prospective Study of Ultrasound to Detect Cystic Fibrosis-related Liver Disease in Children","volume":"75","author":"Schwarzenberg","year":"2022","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/MPG.0b013e31829ef82c","article-title":"Health-related quality of life in children with autoimmune liver disease","volume":"57","author":"Gulati","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MPG.0b013e318185998f","article-title":"Impact of hepatitis C virus infection on children and their caregivers: Quality of life, cognitive, and emotional outcomes","volume":"48","author":"Rodrigue","year":"2009","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jcf.2019.06.017","article-title":"Supersonic shear-wave elastography and APRI for the detection and staging of liver disease in pediatric cystic fibrosis","volume":"19","author":"Calvopina","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e21861","DOI":"10.1016\/j.heliyon.2023.e21861","article-title":"Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools","volume":"9","author":"Scott","year":"2023","journal-title":"Heliyon"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Colomba, J., Netedu, S.R., Lehoux-Dubois, C., Coriati, A., Boudreau, V., Tremblay, F., Cusi, K., Rabasa-Lhoret, R., and Leey, J.A. (2019). Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0219855"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jcf.2022.06.008","article-title":"ELX\/TEZ\/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?","volume":"21","author":"Gardiner","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e1129-48","DOI":"10.1542\/peds.2014-0352","article-title":"Self-reported quality of life of young children with conditions from early infancy: A systematic review","volume":"134","author":"Jardine","year":"2014","journal-title":"Pediatrics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.cgh.2014.02.016","article-title":"Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease","volume":"12","author":"Williet","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/5\/538\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:38Z","timestamp":1760105318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/5\/538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,3]]},"references-count":112,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["diagnostics14050538"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14050538","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,3]]}}}